Natasha Aleksova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natasha Aleksova has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Heather J. Ross
Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
7 shared publicationsFarid Foroutan
5 shared publications- Farid Foroutan
Ted Rogers Centre for Heart Research, University Health Network, Toronto, Ontario, Canada
4 shared publications - Sharon Chih
Heart Failure and Transplantation, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
4 shared publications - Yasbanoo Moayedi
University Health Network, Toronto, Ontario, Canada
4 shared publications Ana C. Alba
Women's College Hospital, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Ontario, Canada
3 shared publications
Latest Publications
- 22 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014462
Examining Status Exceptions in the 2018 Heart Allocation Policy: Is It Time for Another Revision?
- 22 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014462
Examining Status Exceptions in the 2018 Heart Allocation Policy: Is It Time for Another Revision?
- Open Access
Gene expression profiling does not predict long-term risk of malignancy in heart transplant recipients
- Open Access
- 29 September 2025
- Published by Catalytic Health in Canadian Cardiology Today
- p. 23–30
Contemporary Management of Heart Failure with Preserved Ejection Fraction: What is Current and What Lies Ahead?
In Canada, the incidence of heart failure (HF) among adults ≥40 years has increased from 521 per 100,000 to 601 per 100,000 from 2013 to 2023, and is expected to rise further in the coming decades. HF is the second leading cause of death in Canada, with an age standardized all-cause mortality rate of 5,761 per 100,000 compared to people without HF at 913 per 100,000. HF with preserved ejection fraction (HFpEF), defined as the clinical syndrome of HF with left-ventricular ejection fraction (LVEF) ≥50%, comprises approximately half of all HF diagnoses. Contemporary data published this year suggests one- and five-year mortality rates for HFpEF are similar to those seen in heart failure with reduced ejection fraction (HFrEF). The Canadian Cardiovascular Society (CCS) endorses the universal definition of HF, which classifies HFpEF as having an LVEF cutoff of 50% and emphasizes markers of increased left ventricular (LV) filling pressures as a reflection of the underlying pathophysiology. HFpEF is associated with both functional and structural cardiac abnormalities, including diastolic dysfunction, ventricular and atrial remodelling, LV hypertrophy, and fibrosis.5 In addition, systemic inflammation, endothelial dysfunction, altered myocardial energetics, and abnormalities in skeletal muscle are increasingly recognized as important contributors to HFpEF pathophysiology and serve as therapeutic targets. Comorbid conditions including type 2 diabetes mellitus (T2DM), obesity, atrial fibrillation, chronic kidney disease, pulmonary hypertension, obstructive sleep apnea, and iron deficiency have been associated with the development and progression of HFpEF. Furthermore, there is growing interest in identifying distinct HFpEF phenotypes to better characterize patient populations beyond their comorbid conditions, with the aim of personalizing prognosis and treatment options. In a recent study, three distinct HFpEF phenotypes were identified, including a younger group with primarily New York Heart Association (NYHA) II symptoms, a higher prevalence of smoking, and a lower prevalence of diabetes and chronic kidney disease; another consisting of older age individuals (mean age 77 years), predominantly women with atrial fibrillation and chronic kidney disease; and a third group of intermediate age (mean age 66 years) with a very high prevalence of obesity and diabetes, greater functional impairment, and elevated inflammatory markers. Notably, the patients in this latter phenotype, with a very high prevalence of obesity and diabetes, were most likely to be hospitalized for HF along with having an overall mortality risk comparable to those patients classified in the older, atrial fibrillation, chronic kidney disease phenotype, despite their younger age.
- 29 September 2025
- Published by Catalytic Health in Canadian Cardiology Today
- p. 23–30
Open AccessContemporary Management of Heart Failure with Preserved Ejection Fraction: What is Current and What Lies Ahead?
In Canada, the incidence of heart failure (HF) among adults ≥40 years has increased from 521 per 100,000 to 601 per 100,000 from 2013 to 2023, and is expected to rise further in the coming decades. HF is the second leading cause of death in Canada, with an age standardized all-cause mortality rate of 5,761 per 100,000 compared to people without HF at 913 per 100,000. HF with preserved ejection fraction (HFpEF), defined as the clinical syndrome of HF with left-ventricular ejection fraction (LVEF) ≥50%, comprises approximately half of all HF diagnoses. Contemporary data published this year suggests one- and five-year mortality rates for HFpEF are similar to those seen in heart failure with reduced ejection fraction (HFrEF). The Canadian Cardiovascular Society (CCS) endorses the universal definition of HF, which classifies HFpEF as having an LVEF cutoff of 50% and emphasizes markers of increased left ventricular (LV) filling pressures as a reflection of the underlying pathophysiology. HFpEF is associated with both functional and structural cardiac abnormalities, including diastolic dysfunction, ventricular and atrial remodelling, LV hypertrophy, and fibrosis.5 In addition, systemic inflammation, endothelial dysfunction, altered myocardial energetics, and abnormalities in skeletal muscle are increasingly recognized as important contributors to HFpEF pathophysiology and serve as therapeutic targets. Comorbid conditions including type 2 diabetes mellitus (T2DM), obesity, atrial fibrillation, chronic kidney disease, pulmonary hypertension, obstructive sleep apnea, and iron deficiency have been associated with the development and progression of HFpEF. Furthermore, there is growing interest in identifying distinct HFpEF phenotypes to better characterize patient populations beyond their comorbid conditions, with the aim of personalizing prognosis and treatment options. In a recent study, three distinct HFpEF phenotypes were identified, including a younger group with primarily New York Heart Association (NYHA) II symptoms, a higher prevalence of smoking, and a lower prevalence of diabetes and chronic kidney disease; another consisting of older age individuals (mean age 77 years), predominantly women with atrial fibrillation and chronic kidney disease; and a third group of intermediate age (mean age 66 years) with a very high prevalence of obesity and diabetes, greater functional impairment, and elevated inflammatory markers. Notably, the patients in this latter phenotype, with a very high prevalence of obesity and diabetes, were most likely to be hospitalized for HF along with having an overall mortality risk comparable to those patients classified in the older, atrial fibrillation, chronic kidney disease phenotype, despite their younger age.
- 12 February 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (2) , e70100
Clinical Practice Recommendations on the Effect of COVID‐19 Vaccination Strategies on Outcomes in Solid Organ Transplant Recipients
Introduction: Solid organ transplant (SOT) recipients were excluded from clinical trials evaluating the efficacy of COVID‐19 vaccines. There is uncertainty about the number of doses required to prevent life‐threatening infection, as well as uncertainty in the optimal vaccine type and their durability. Our objectives were to provide recommendations on the number of COVID‐19 vaccination doses, type of vaccine, dose of vaccine administered, and timing of vaccination in SOT recipients.Methods: We commissioned a systematic review on COVID‐19 vaccination in SOT, focusing on patient‐important outcomes. We recruited an international, multidisciplinary panel of 18 stakeholders, including patient partners to summarize our findings using the GRADE (grading of recommendation, assessment, development, and evaluation) framework, rate certainty in the evidence, and develop recommendations.Results: Our panel recommends the routine provision of additional COVID‐19 doses after the primary series to SOT recipients with variant‐appropriate vaccines (strong recommendation, low certainty evidence). We suggest using any available WHO‐approved vaccine rather than selectively choosing a specific type and receiving a single dose rather than a double dose of any COVID‐19 vaccine booster (weak recommendation, low certainty evidence). Lastly, we suggest vaccination before transplantation when possible (weak recommendation, low certainty evidence).Conclusion: The evidence used to guide these recommendations is limited by the paucity of robust randomized trials evaluating COVID‐19 vaccination strategies and clinical outcomes in the SOT population. The provision of higher‐quality evidence of the overall effects of COVID‐19 vaccination in SOT to inform clinical practice will require large, randomized trials.
- 12 February 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (2) , e70100
Clinical Practice Recommendations on the Effect of COVID‐19 Vaccination Strategies on Outcomes in Solid Organ Transplant Recipients
Introduction: Solid organ transplant (SOT) recipients were excluded from clinical trials evaluating the efficacy of COVID‐19 vaccines. There is uncertainty about the number of doses required to prevent life‐threatening infection, as well as uncertainty in the optimal vaccine type and their durability. Our objectives were to provide recommendations on the number of COVID‐19 vaccination doses, type of vaccine, dose of vaccine administered, and timing of vaccination in SOT recipients.Methods: We commissioned a systematic review on COVID‐19 vaccination in SOT, focusing on patient‐important outcomes. We recruited an international, multidisciplinary panel of 18 stakeholders, including patient partners to summarize our findings using the GRADE (grading of recommendation, assessment, development, and evaluation) framework, rate certainty in the evidence, and develop recommendations.Results: Our panel recommends the routine provision of additional COVID‐19 doses after the primary series to SOT recipients with variant‐appropriate vaccines (strong recommendation, low certainty evidence). We suggest using any available WHO‐approved vaccine rather than selectively choosing a specific type and receiving a single dose rather than a double dose of any COVID‐19 vaccine booster (weak recommendation, low certainty evidence). Lastly, we suggest vaccination before transplantation when possible (weak recommendation, low certainty evidence).Conclusion: The evidence used to guide these recommendations is limited by the paucity of robust randomized trials evaluating COVID‐19 vaccination strategies and clinical outcomes in the SOT population. The provision of higher‐quality evidence of the overall effects of COVID‐19 vaccination in SOT to inform clinical practice will require large, randomized trials.
- Open Access
- 1 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (12) , 2269-2281
Efficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis
- 1 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (12) , 2269-2281
Open AccessEfficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis
- 1 February 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (2) , e011306
Enhancing the Prediction of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound and Machine Learning: A Proof of Concept
BACKGROUND: Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in heart transplantation. Building on previous unsupervised learning models, we sought to identify CAV clusters using serial maximal intimal thickness and baseline clinical risk factors to predict the development of early CAV. METHODS: This is a single-center retrospective study including adult heart transplantation recipients. A latent class mixed-effects model was used to identify patient clusters with similar trajectories of maximal intimal thickness posttransplant and pretransplant covariates associated with each cluster. RESULTS: Among 186 heart transplantation recipients, we identified 4 patient phenotypes: very low, low, moderate, and high risk. The 5-year risk (95% CI) of the International Society for Heart and Lung Transplantation–defined CAV in the high, moderate, low, and very low risk groups was 49.1% (35.2%–68.5%), 23.4% (13.3%–41.2%), 5.0% (1.3%–19.6%), and 0%, respectively. Only patients in the moderate to high risk cluster developed the International Society for Heart and Lung Transplantation CAV 2-3 at 5 years ( P =0.02). Of the 4 groups, the low risk group had significantly younger female recipients, shorter ischemic time, and younger female donors compared with the high risk group. CONCLUSIONS: We identified 4 clusters characterized by distinct maximal intimal thickness trajectories. These clusters were shown to discriminate against the development of angiographic CAV. This approach allows for the personalization of surveillance and CAV-directed treatment before the development of angiographically apparent disease.
- 1 February 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (2) , e011306
Enhancing the Prediction of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound and Machine Learning: A Proof of Concept
BACKGROUND: Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in heart transplantation. Building on previous unsupervised learning models, we sought to identify CAV clusters using serial maximal intimal thickness and baseline clinical risk factors to predict the development of early CAV. METHODS: This is a single-center retrospective study including adult heart transplantation recipients. A latent class mixed-effects model was used to identify patient clusters with similar trajectories of maximal intimal thickness posttransplant and pretransplant covariates associated with each cluster. RESULTS: Among 186 heart transplantation recipients, we identified 4 patient phenotypes: very low, low, moderate, and high risk. The 5-year risk (95% CI) of the International Society for Heart and Lung Transplantation–defined CAV in the high, moderate, low, and very low risk groups was 49.1% (35.2%–68.5%), 23.4% (13.3%–41.2%), 5.0% (1.3%–19.6%), and 0%, respectively. Only patients in the moderate to high risk cluster developed the International Society for Heart and Lung Transplantation CAV 2-3 at 5 years ( P =0.02). Of the 4 groups, the low risk group had significantly younger female recipients, shorter ischemic time, and younger female donors compared with the high risk group. CONCLUSIONS: We identified 4 clusters characterized by distinct maximal intimal thickness trajectories. These clusters were shown to discriminate against the development of angiographic CAV. This approach allows for the personalization of surveillance and CAV-directed treatment before the development of angiographically apparent disease.